3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Dermatologic
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
fludarabine
63
Cyclophosphamide
63
venetoclax
58
Azacitidine
54
fludarabine phosphate
50
Specimen Handling
44
ruxolitinib
40
Whole-Body Irradiation
40
Mycophenolic Acid
37
Tacrolimus
35
Melphalan
32
Busulfan
32
Biopsy
32
Cytarabine
31
Decitabine
28
Stem Cell Transplantation
27
Granulocyte Colony-Stimulating Factor
21
Injections
20
asciminib
19
decitabine and cedazuridine drug combination
18
Sirolimus
18
Peripheral Blood Stem Cell Transplantation
18
Thiotepa
17
Filgrastim
17
nilotinib
16
X-Rays
14
Methotrexate
14
Imatinib Mesylate
14
Cyclosporine
14
Magnetic Resonance Spectroscopy
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
peginterferon alfa-2a
×
Myeloid
×
1 year
×
Clear all
NCT02201459
2025-10-02
PETALs
Hospices Civils de Lyon
Phase 3
Completed
200 enrolled